Health Technology Appraisal – bortezomib monotherapy for relapsed multiple myeloma

Myeloma UK response to the 3 bortezomib scenarios made by the Appeal Panel

Myeloma UK would like to reiterate the stance it has held throughout this appraisal: that no patient should die without having access to bortezomib.

We have already communicated to the Institute that the ongoing appraisal should consider combination therapy to avoid duplication of effort, generating confusion out in the health service, and most importantly to avoid the repercussions separate appraisals may have for patients - that is, denying them access to the most effective use of this significant treatment.

Should this not be achievable by 8 May, then we are in favour of an approval of bortezomib monotherapy without the incorporation of the response programme, as we feel there are issues of implementation and sustainability that can be otherwise avoided through adoption of either scenario 1 or 2.

However, if approval is determinant on adopting the response scheme, then Myeloma UK will fully support it and will do everything possible as an organisation to get behind its execution.

Our fundamental desire is that a solution is found for patients that best facilitates their access to this important treatment.

Myeloma UK

Lower Ground Floor, 37 York Place, Edinburgh EH1 3HP Tel: 0131 557 3332 Fax: 0131 556 9720 www.myeloma.org.uk myelomauk@myeloma.org.uk
Company No.190563 Charity No. SC 026116 Myeloma UK is an Investor in People
Myeloma Infoline 0800 980 3332